Relationship between microRNA-27a and efficacy of neoadjuvant chemotherapy in gastric cancer and its mechanism in gastric cancer cell growth and metastasis

Xu, Chengcheng; Cheng, Hong; Li, Na; Zhou, Ning; Tang, Xushan

doi:10.1042/bsr20181175

Cited by 8 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In gastric cancer, there are several studies showing that miR-27a can be a good candidate as a biomarker for diagnosis and prognosis (30, 103, 105, 110, 111). From 164 gastric cancer patients and 127 normal people, miR-27a was identified to have a markedly higher confidence interval (0.879) than those of carcinoembryonic antigen (CEA) (0.503) and carbohydrate antigen 19-9 (CA19-9) (0.600), indicating that miR-27a can serve as a biomarker for gastric cancer diagnosis (102).…”

Section: Mir-27a In Clinical Applicationsmentioning

confidence: 99%

“…In a novel study, the serum level of exosomal miR-27a was detected in 74 gastric cancer patients who received neoadjuvant chemotherapy by qRT-PCR, and the expression of miR-27a in the serum of gastric cancer patients decreased significantly after neoadjuvant chemotherapy. Gastric cancer patients who had a higher level of miR-27a tended to have tumor invasion and migration, indicating poor efficacy and prognosis after neoadjuvant chemotherapy (110). In another study, patients with upregulated miR-27a expression had significantly worse overall survival (OS) than patients with lower miR-27a expression ( P = 0.024), while a higher miR-27a expression level indicated resistance to fluoropyrimidine-based chemotherapy (105).…”

Section: Mir-27a In Clinical Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations

Zhang

Cao

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a family of highly conserved, non-coding single-stranded RNAs transcribed as ~70 nucleotide precursors to an 18–22 nucleotide product (1). miRNAs can silence their homologous target genes at the post-transcriptional level, and these genes have been revealed to play an important role in tumorigenesis, invasion and metastasis (2). MicroRNA-27a (miR-27a), transcripted by miR-27a gene, has proved to implicate with many kinds of solid tumors, showing potential as a useful biomarker or drug target for clinical application. However, even though miR-27a has been reported in many cancers, the mechanism and signal pathways of miR-27 in oncogenesis, invasion, and metastasis are still obscure. Moreover, recent studies show that miR-27a pays an important role in epithelial-mesenchymal-transition, regulating tumor immune response, and chemoresistance. In this review, we summarize the current literature, demonstrate the established link between miR-27a and tumorigenesis, and focus on recently identified mechanisms. The review also aims to demonstrate the potential of miR-27a as a diagnostic and/or prognostic biomarker in solid tumors and to discuss the possibilities of targeted therapy and drug design.

show abstract

Section: Mir-27a In Clinical Applicationsmentioning

confidence: 99%

Section: Mir-27a In Clinical Applicationsmentioning

confidence: 99%

MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations

Zhang

Cao

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…11 MiR-27a-3p is considered an oncogene because its overexpression is associated with a poor prognosis, as observed in patients with osteosarcoma or gastric cancer. 12,13 Some reports have found that miR-27a-3p enhances colon cancer progression and differentiation. 14 Besides, miR-27a-3p has been demonstrated to mediate chemoresistance of cancers such as leukemia, ovarian cancer, and hepatocellular carcinoma.…”

Section: Introductionmentioning

confidence: 99%

<p>MicroRNA-27a-3p Reverses Adriamycin Resistance by Targeting BTG2 and Activating PI3K/Akt Pathway in Breast Cancer Cells</p>

Zhu¹,

Chen²,

Fu³

et al. 2020

OTT

View full text Add to dashboard Cite

Aim: This study aimed to explore the regulative mechanisms of miR-27a-3p in chemoresistance of breast cancer cells. Materials and Methods: qRT-PCR was employed to determine miR-27a-3p expression in two breast cancer cell lines, MCF-7 and MCF-7/adriamycin-resistant cell line (MCF-7/ADR). The two cell lines were treated with miR-27a-3p mimics or inhibitors or corresponding negative control (NC), respectively. The changes were investigated by qRT-PCR, CCK-8 assay, Western blot (WB), colony formation assay, and flow cytometry assay. Moreover, luciferase reporter assay was analyzed to verify the downstream target gene of miR-27a-3p. Further investigation in the correlation between miR-27a-3p and BTG2 was launched by WB, flow cytometry assay, and CCK-8 assay. The expression of Akt and p-Akt was detected by WB. Key Findings: Significantly higher miR-27a-3p expression was confirmed in MCF-7/ADR as compared with sensitive cell line MCF-7 (P<0.05). The down-regulation of miR-27a-3p in MCF-7/ADR enhanced the sensitivity of cancer cells to adriamycin treatment, decreased multidrug resistance gene 1/P-glycoprotein (MDR1/P-gp) expression, enhanced the apoptosis-related proteins expression, increased adriamycin-induced apoptosis, and inhibited cell proliferation as compared to NC groups (P<0.05). The up-regulation of miR-27a-3p in MCF-7 showed the opposite results. BTG2 is identified as a direct target of miR-27a-3p and its down-regulation reversed ADR-resistance. BTG2 treatment exhibited inhibitory effect on PI3K/Akt pathway in MCF-7/ADR cells. Significance: miR-27a-3p might be associated with resistance of breast cancer cells to adriamycin treatments, modulating cell proliferation and apoptosis by targeting BTG2 and promoting the PI3K/Akt pathway in breast cancer cells. miR-27a-3p/BTG2 axis might be a potential therapeutic target for clinical BC resistance.

show abstract

“…Accumulating evidence suggests that various non-coding regulatory miRNAs, including miR-27a, miR-196a-1, miR-208a and miR-206, also serve a prominent role in the activation of the Wnt/β-catenin signaling pathway by inactivating SFRP1, which induces GC cell proliferation, migration, invasion and metastasis (46,(75)(76)(77)(78)(79)(80). In addition, long non-coding RNAs (lncRNAs) are also emerging as key players in mediating this process (81).…”

Section: Discussionmentioning

confidence: 99%

Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma

et al. 2021

View full text Add to dashboard Cite

Diffuse gastric carcinoma (DGC) is characterized by poorly cohesive cells, highly invasive growth patterns, poor prognosis and resistance to the majority of available systemic therapeutic strategies. It has been previously reported that the Wnt/β-catenin signaling pathway serves a prominent role in the tumorigenesis of gastric carcinoma. However, the mechanism underlying the dysregulation of this pathway in DGC has not been fully elucidated. Therefore, the present study aimed to investigate the expression profiles of Wnt antagonists, secreted frizzled-related protein 1 (SFRP1) and secreted frizzled-related protein 3 (SFRP3), and dishevelled protein family members, dishevelled segment polarity protein 2 (DVL2) and dishevelled segment polarity protein 3 (DVL3), in DGC tissues. The association between the expression levels of these factors and the clinicopathological parameters of the patients was determined. Protein and mRNA expression levels in 62 DGC tumor tissues and 62 normal gastric mucosal tissues obtained from patients with non-malignant disease were measured using immunohistochemical and reverse transcription-quantitative PCR (RT-qPCR) analysis. Significantly lower protein expression levels of SFRP1 (P<0.001) and SFRP3 (P<0.001), but significantly higher protein expression levels of DVL2 (P<0.001) and DVL3 (P<0.001) were observed in DGC tissues compared with in control tissues by immunohistochemistry. In addition, significantly lower expression levels of SFRP1 (P<0.05) and higher expression levels of DVL3 (P<0.05) were found in in DGC tissues compared with those in normal gastric mucosal tissues using RT-qPCR. According to correlation analysis between the SFRP1, SFRP3, DVL2 and DVL3 protein expression levels and the clinicopathological characteristics of patients with DGC, a statistically significant correlation was found between the SFRP3 volume density and T stage (r=0.304; P=0.017) and between the SFRP3 volume density and clinical stage (r=0.336; P=0.008). In conclusion, the findings of the present study suggested that the Wnt signaling pathway components SFRP1, SFRP3, DVL2 and DVL3 may be aberrantly expressed in DGC tissues, implicating their possible role in the development of this malignant disease. The present data also revealed a positive relationship between SFRP3 protein expression and the clinical and T stage of DGC.

show abstract

Relationship between microRNA-27a and efficacy of neoadjuvant chemotherapy in gastric cancer and its mechanism in gastric cancer cell growth and metastasis

Cited by 8 publications

References 30 publications

MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations

MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations

<p>MicroRNA-27a-3p Reverses Adriamycin Resistance by Targeting BTG2 and Activating PI3K/Akt Pathway in Breast Cancer Cells</p>

Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma

Contact Info

Product

Resources

About